300558 贝达药业
交易中 09-08 10:27:39
资讯
新帖
简况
贝达药业：巴替利单抗和泽弗利单抗处于临床前研究阶段
证券之星 · 09-07 17:39
贝达药业：巴替利单抗和泽弗利单抗处于临床前研究阶段
贝达药业：BPI-572270和MCLA-129是公司重点推进的新药项目
证券之星 · 09-07 17:21
贝达药业：BPI-572270和MCLA-129是公司重点推进的新药项目
贝达药业(300558.SZ)：盐酸恩沙替尼胶囊术后辅助治疗适应症获得药品注册证书
智通财经 · 09-03
贝达药业(300558.SZ)：盐酸恩沙替尼胶囊术后辅助治疗适应症获得药品注册证书
毛利率下滑、眼科新药临床失利，贝达药业四度递表港交所
同花顺 · 09-02
毛利率下滑、眼科新药临床失利，贝达药业四度递表港交所
这家“最会赚钱的创新药第一股”，贝达药业赴港IPO，未来悬念重重……
市场资讯 · 09-02
这家“最会赚钱的创新药第一股”，贝达药业赴港IPO，未来悬念重重……
股市必读：贝达药业新发布《关于重新向香港联交所递交境外上市股份（H股）发行上市申请并刊发申请资料的公告》
证券之星 · 09-01
股市必读：贝达药业新发布《关于重新向香港联交所递交境外上市股份（H股）发行上市申请并刊发申请资料的公告》
贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押930万股，占总股本2.2%
证券之星 · 08-31
贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押930万股，占总股本2.2%
贝达药业重新递交H股上市申请
同花顺 · 08-30
贝达药业重新递交H股上市申请
贝达药业：WCLC多项创新研究成果入选
证券之星 · 08-27
贝达药业：WCLC多项创新研究成果入选
贝达药业(300558)7月31日股东户数4.27万户，较上期减少14.27%
证券之星 · 08-27
贝达药业(300558)7月31日股东户数4.27万户，较上期减少14.27%
贝达药业涨6.32%，东海证券二周前给出“买入”评级
证券之星 · 08-27
贝达药业涨6.32%，东海证券二周前给出“买入”评级
贝达药业：BPI-572270的I期临床研究正处于剂量爬坡和剂量回填阶段
证券之星 · 08-27
贝达药业：BPI-572270的I期临床研究正处于剂量爬坡和剂量回填阶段
贝达药业：截至2026年7月31日，公司A股普通股股东总数为42,674户
证券之星 · 08-27
贝达药业：截至2026年7月31日，公司A股普通股股东总数为42,674户
8月24日贝达药业跌5.18%，富国精准医疗混合A基金重仓该股
证券之星 · 08-24
8月24日贝达药业跌5.18%，富国精准医疗混合A基金重仓该股
贝达药业（300558）2026年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 08-22
贝达药业（300558）2026年中报简析：营收净利润同比双双增长，应收账款上升
贝达药业(300558)6月30日股东户数4.98万户，较上期增加23.47%
证券之星 · 08-21
贝达药业(300558)6月30日股东户数4.98万户，较上期增加23.47%
贝达药业：上半年净利润同比增长115.97%
格隆汇 · 08-20
贝达药业：上半年净利润同比增长115.97%
贝达药业最新公告：2026年半年度净利润同比增长115.97%
证券之星 · 08-20
贝达药业最新公告：2026年半年度净利润同比增长115.97%
贝达药业涨8.85%，东海证券一周前给出“买入”评级
证券之星 · 08-20
贝达药业涨8.85%，东海证券一周前给出“买入”评级
贝达药业（300558）披露合作伙伴EyePoint公布DURAVYU III期临床首项试验数据，8月19日股价下跌8.17%
证券之星 · 08-19
贝达药业（300558）披露合作伙伴EyePoint公布DURAVYU III期临床首项试验数据，8月19日股价下跌8.17%
加载更多
公司概况
公司名称：
贝达药业股份有限公司
所属行业：
医药制造业
上市日期：
2016-11-07
主营业务：
贝达药业股份有限公司的主营业务是自主知识产权创新药物研究与开发。公司的主要产品是盐酸埃克替尼片（商品名：凯美纳）、盐酸恩沙替尼胶囊（商品名：贝美纳）、贝伐珠单抗注射液（MIL60，商品名：贝安汀）、甲磺酸贝福替尼胶囊（BPI-D0316，商品名：赛美纳）、伏罗尼布片（CM082，商品名：伏美纳）、酒石酸泰瑞西利胶囊（BPI-16350，商品名：康美纳）、注射用曲妥珠单抗（商品名：安瑞泽）、重组人白蛋白注射液（水稻）（商品名：奥福民）、帕妥珠单抗注射液（商品名：贝泽汀）。
发行价格：
17.57
{"stockData":{"symbol":"300558","market":"SZ","secType":"STK","nameCN":"贝达药业","latestPrice":47.45,"timestamp":1788834459000,"preClose":48.3,"halted":0,"volume":4551038,"delay":0,"changeRate":-0.0176,"floatShares":422000000,"shares":423000000,"eps":1.1045,"marketStatus":"交易中","change":-0.85,"latestTime":"09-08 10:27:39","open":48.3,"high":48.46,"low":47.26,"amount":217000000,"amplitude":0.0248,"askPrice":47.45,"askSize":78,"bidPrice":47.44,"bidSize":5,"shortable":0,"etf":0,"ttmEps":1.1045,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1788838200000},"marketStatusCode":2,"adr":0,"adjPreClose":48.3,"symbolType":"stock","openAndCloseTimeList":[[1788831000000,1788838200000],[1788843600000,1788850800000]],"highLimit":53.13,"lowLimit":43.47,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":423331685,"isCdr":false,"pbRate":3.09,"roa":"--","peRate":42.960616,"roe":"4.61%","epsLYR":0.73,"committee":-0.461255,"marketValue":20087000000,"turnoverRate":0.0108,"status":1,"floatMarketCap":20032000000},"requestUrl":"/m/hq/s/300558","defaultTab":"news","newsList":[{"id":"2665131194","title":"贝达药业：巴替利单抗和泽弗利单抗处于临床前研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2665131194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665131194?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:39","pubTimestamp":1788773947,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月07日在投资者关系平台上答复投资者关心的问题。公司从艾吉纳斯引进的巴替利单抗和泽弗利单抗目前处于临床前研究阶段，拟开发适应症为非小细胞肺癌、肝癌。曲妥珠单抗属于国家医保乙类药品，患者可以在医保规定范围之内报销。针对康美纳，公司有专门团队负责该产品的商业化策略和计划，目前尚未纳入医保目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300558","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665194343","title":"贝达药业：BPI-572270和MCLA-129是公司重点推进的新药项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2665194343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665194343?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:21","pubTimestamp":1788772874,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业09月07日在投资者关系平台上答复投资者关心的问题。投资者提问：毛力教授在访谈时提到未来公司重要项目572270和129+恩沙。BPI-572270和MCLA-129是公司重点推进的新药项目，目前国内的临床研究工作正在有序推进。海外临床需要综合考虑国内临床数据反馈、境外市场潜力及竞争态势等多种因素，如有境外临床申报，公司将及时公告披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700022128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664822029","title":"贝达药业(300558.SZ)：盐酸恩沙替尼胶囊术后辅助治疗适应症获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2664822029","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664822029?lang=zh_cn&edition=full","pubTime":"2026-09-03 15:50","pubTimestamp":1788421858,"startTime":"0","endTime":"0","summary":"智通财经APP讯，贝达药业(300558.SZ)发布公告，今日，公司收到国家药品监督管理局(简称“NMPA”)签发的关于盐酸恩沙替尼胶囊(商品名：贝美纳®，简称“恩沙替尼”)用于“间变性淋巴瘤激酶(ALK)阳性的IB期至IIIB期非小细胞肺癌患者的术后辅助治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”(简称“术后辅助治疗适应症”)的《药品注册证书》，这是恩沙替尼获批的第三项适应症。取得《药品注册证书》后，公司即可在所获批的术后辅助治疗适应症上使用本品，此次获批对公司营业收入具有积极作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664485892","title":"毛利率下滑、眼科新药临床失利，贝达药业四度递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2664485892","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664485892?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:17","pubTimestamp":1788337020,"startTime":"0","endTime":"0","summary":"贝达药业股份有限公司（以下简称“贝达药业”）近日重新向香港联合交易所有限公司递交了发行境外上市股份（H股）并在香港联交所主板挂牌上市的申请。这已经是贝达药业第四次冲刺港股，前三 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260902/c679529274.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260902/c679529274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0060","BK0239","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664867024","title":"这家“最会赚钱的创新药第一股”，贝达药业赴港IPO，未来悬念重重……","url":"https://stock-news.laohu8.com/highlight/detail?id=2664867024","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664867024?lang=zh_cn&edition=full","pubTime":"2026-09-02 08:53","pubTimestamp":1788310380,"startTime":"0","endTime":"0","summary":"老药的余晖埃克替尼之于贝达药业，是起点，也是命脉。仿制药上市后几乎必然以低价渗透市场，一旦竞争充分，埃克替尼或将被迫卷入国家或地区集中带量采购，面临进一步的降价压力。招股书承认，协议项下合计人民币1.8亿元的若干监管里程碑付款已被触发，并成为公司的应付款项。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-02/doc-iniqkvce1333036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["REDS","BK0060","159992","BK4127","FRHC","BK1161","LNGR","BK1574","06978","MEDX","IBBQ","300558","KCE","BK0239","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664075170","title":"股市必读：贝达药业新发布《关于重新向香港联交所递交境外上市股份（H股）发行上市申请并刊发申请资料的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664075170","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664075170?lang=zh_cn&edition=full","pubTime":"2026-09-01 01:02","pubTimestamp":1788195743,"startTime":"0","endTime":"0","summary":"公司公告汇总关于重新向香港联交所递交境外上市股份（H股）发行上市申请并刊发申请资料的公告贝达药业股份有限公司已于2026年8月28日重新向香港联合交易所有限公司递交发行境外上市股份（H股）并在香港联交所主板上市的申请，并于同日在香港联交所网站刊发了申请资料。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100001689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663824072","title":"贝达药业（300558）股东宁波凯铭投资管理合伙企业(有限合伙)质押930万股，占总股本2.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663824072","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663824072?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:32","pubTimestamp":1788172372,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业8月31日公开信息显示，股东宁波凯铭投资管理合伙企业向渤海国际信托股份有限公司合计质押930.0万股，占总股本2.2%。质押详情见下表：截止本公告日，股东宁波凯铭投资管理合伙企业已累计质押股份4797.85万股，占其持股总数的59.93%。贝达药业主营业务：致力于新药研发和推广,以解决肺癌等恶性肿瘤治疗领域中未被满足的临床需求。本文数据来源于贝达药业公告，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100028872.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044842","title":"贝达药业重新递交H股上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044842","media":"同花顺","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663044842?lang=zh_cn&edition=full","pubTime":"2026-08-30 20:05","pubTimestamp":1788091500,"startTime":"0","endTime":"0","summary":"北京商报讯(记者董亮王悦彤)8月30日晚间，贝达药业(300558)披露公告称，公司已于2026年8月28日重新向香港联交所递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请，并于同日在 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260830/c679420200.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260830/c679420200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0060","300558","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662294706","title":"贝达药业：WCLC多项创新研究成果入选","url":"https://stock-news.laohu8.com/highlight/detail?id=2662294706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662294706?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:48","pubTimestamp":1787827690,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)08月27日在投资者关系平台上答复投资者关心的问题。投资者提问：wclc和esmo你们有哪些研究公布？贝达药业回复：您好！WCLC是世界上最大的致力于肺癌和其他胸部恶性肿瘤的多学科肿瘤会议，贝达药业及控股子公司Xcovery多项创新研究成果入选本次会议。详细情况请关注公司\"贝达药业投资者关系\"微信公众号的相关信息发布。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700044973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662705832","title":"贝达药业(300558)7月31日股东户数4.27万户，较上期减少14.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662705832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662705832?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:14","pubTimestamp":1787825667,"startTime":"0","endTime":"0","summary":"证券之星消息，近日贝达药业披露，截至2026年7月31日公司股东户数为4.27万户，较6月30日减少7103.0户，减幅为14.27%。在化学制药行业个股中，贝达药业股东户数高于行业平均水平，截至7月31日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年6月30日至2026年7月31日，贝达药业区间跌幅为11.63%，在此期间股东户数减少7103.0户，减幅为14.27%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700043720.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662747417","title":"贝达药业涨6.32%，东海证券二周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2662747417","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662747417?lang=zh_cn&edition=full","pubTime":"2026-08-27 16:52","pubTimestamp":1787820773,"startTime":"0","endTime":"0","summary":"今日贝达药业涨6.32%，收盘报51.47元。2026年8月12日，东海证券研究员杜永宏发布了对贝达药业的研报《公司简评报告：产品矩阵持续丰富，研发进展快速推进》，该研报对贝达药业给出“买入”评级。研报中预计公司2026-2028年实现归母净利润分别为5.89/7.47/9.11亿元，对应EPS分别为1.39/1.76/2.15元，对应PE分别为48.94/38.60/31.65倍。贝达药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700039373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662726136","title":"贝达药业：BPI-572270的I期临床研究正处于剂量爬坡和剂量回填阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2662726136","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662726136?lang=zh_cn&edition=full","pubTime":"2026-08-27 08:45","pubTimestamp":1787791517,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)08月27日在投资者关系平台上答复投资者关心的问题。投资者提问：百济神州的panras近期启动了全球临床，你们的572270有资金完成吗，为什么还没有bd出去？是不是又打算赶了早集然后不吃饭？贝达药业回复：您好！BPI-572270的I期临床研究正处于剂量爬坡和剂量回填阶段，整体推进顺利。公司高度重视BD合作，如有重大进展公司将及时公告披露。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700016623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662726619","title":"贝达药业：截至2026年7月31日，公司A股普通股股东总数为42,674户","url":"https://stock-news.laohu8.com/highlight/detail?id=2662726619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662726619?lang=zh_cn&edition=full","pubTime":"2026-08-27 08:42","pubTimestamp":1787791339,"startTime":"0","endTime":"0","summary":"证券之星消息，贝达药业(300558)08月27日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止8月20号，公司的股东人数是多少？谢谢贝达药业回复：您好！截至2026年7月31日，公司A股普通股股东总数为42,674户。公司会每月末更新股东人数信息，您可以通过公司官网（https://www.bettapharma.com/）——投资者关系——互动交流栏目查询。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700016599.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","07233","159982","02827","82846","03188","83188","02846","300558","03130","399300","BK1147","83130","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661224849","title":"8月24日贝达药业跌5.18%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661224849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661224849?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:40","pubTimestamp":1787560852,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日贝达药业跌5.18%，收盘报48.53元，换手率5.38%，成交量22.7万手，成交额11.05亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共44家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.509，较上一交易日下跌3.83%，近一年下跌4.24%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400022124.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661021893","title":"贝达药业（300558）2026年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2661021893","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661021893?lang=zh_cn&edition=full","pubTime":"2026-08-22 06:15","pubTimestamp":1787350536,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期贝达药业发布2026年中报。截至本报告期末，公司营业总收入19.76亿元，同比上升14.12%，归母净利润3.02亿元，同比上升115.97%。按单季度数据看，第二季度营业总收入9.36亿元，同比上升15.02%，第二季度归母净利润6621.74万元，同比上升66.34%。本报告期贝达药业应收账款上升，应收账款同比增幅达260.38%。营业成本变动幅度为42.91%,原因:药品销量增加。本文数据来源于贝达药业2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082200005248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661026973","title":"贝达药业(300558)6月30日股东户数4.98万户，较上期增加23.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661026973","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661026973?lang=zh_cn&edition=full","pubTime":"2026-08-21 17:47","pubTimestamp":1787305633,"startTime":"0","endTime":"0","summary":"证券之星消息，近日贝达药业披露，截至2026年6月30日公司股东户数为4.98万户，较3月31日增加9461.0户，增幅为23.47%。在化学制药行业个股中，贝达药业股东户数高于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.68万户。从股价来看，2026年3月31日至2026年6月30日，贝达药业区间涨幅为49.7%，在此期间股东户数增加9461.0户，增幅为23.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100032821.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660842192","title":"贝达药业：上半年净利润同比增长115.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660842192","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660842192?lang=zh_cn&edition=full","pubTime":"2026-08-20 20:36","pubTimestamp":1787229419,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660284708","title":"贝达药业最新公告：2026年半年度净利润同比增长115.97%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660284708","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660284708?lang=zh_cn&edition=full","pubTime":"2026-08-20 20:29","pubTimestamp":1787228970,"startTime":"0","endTime":"0","summary":"贝达药业(300558.SZ)公告称，公司发布2026年半年度报告，实现营业收入19.76亿元，同比增长14.12%；归属于上市公司股东的净利润3.02亿元，同比增长115.97%。公司计划不派发现金红利，不送红股，不以公积金转增股本。注：公司Q2净利润0.66亿，Q1净利润2.36亿，据此计算，Q2净利润环比下降71%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000041137.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440275","title":"贝达药业涨8.85%，东海证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440275","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660440275?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:42","pubTimestamp":1787215375,"startTime":"0","endTime":"0","summary":"今日贝达药业涨8.85%，收盘报55.7元。2026年8月12日，东海证券研究员杜永宏发布了对贝达药业的研报《公司简评报告：产品矩阵持续丰富，研发进展快速推进》，该研报对贝达药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为37.98%。贝达药业个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000029010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300558","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660441208","title":"贝达药业（300558）披露合作伙伴EyePoint公布DURAVYU III期临床首项试验数据，8月19日股价下跌8.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660441208","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660441208?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:59","pubTimestamp":1787133593,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘，贝达药业报收于51.17元，较前一交易日下跌8.17%，最新总市值为216.62亿元。近日，贝达药业披露其合作伙伴EyePoint公布了DURAVYU治疗湿性年龄相关性黄斑变性开展的两项关键III期临床试验中的首项试验数据。关键次要终点显示DURAVYU安全性良好，治疗负担降低42%，解剖学控制与对照组相当。第二项III期试验LUCIA数据预计2026年第四季度公布，将决定是否提交新药上市申请。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","300558"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788834461264,"stockEarnings":[{"period":"1week","weight":-0.0432},{"period":"1month","weight":-0.3121},{"period":"3month","weight":-0.0557},{"period":"6month","weight":0.1016},{"period":"1year","weight":-0.3448},{"period":"ytd","weight":0.0377}],"compareEarnings":[{"period":"1week","weight":-0.0134},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0193},{"period":"6month","weight":-0.0486},{"period":"1year","weight":0.0315},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贝达药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"42674人(较上一季度减少14.27%)","perCapita":"9893股","listingDate":"2016-11-07","address":"浙江省杭州市临平区经济技术开发区兴中路355号","registeredCapital":"42333万元","survey":" 贝达药业股份有限公司的主营业务是自主知识产权创新药物研究与开发。公司的主要产品是盐酸埃克替尼片（商品名：凯美纳）、盐酸恩沙替尼胶囊（商品名：贝美纳）、贝伐珠单抗注射液（MIL60，商品名：贝安汀）、甲磺酸贝福替尼胶囊（BPI-D0316，商品名：赛美纳）、伏罗尼布片（CM082，商品名：伏美纳）、酒石酸泰瑞西利胶囊（BPI-16350，商品名：康美纳）、注射用曲妥珠单抗（商品名：安瑞泽）、重组人白蛋白注射液（水稻）（商品名：奥福民）、帕妥珠单抗注射液（商品名：贝泽汀）。","listedPrice":17.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"贝达药业,300558,贝达药业股票,贝达药业股票老虎,贝达药业股票老虎国际,贝达药业行情,贝达药业股票行情,贝达药业股价,贝达药业股市,贝达药业股票价格,贝达药业股票交易,贝达药业股票购买,贝达药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"贝达药业(300558)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供贝达药业(300558)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}